文献速递免疫规划卫生政策与健康促进

24价肺炎球菌结合疫苗在50岁及以上成人中的成本效果与预算影响分析

Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older.
PubMed 文献 · Vaccine · 2025-07-01

研究用马尔可夫决策分析模型比较PCV24与现有推荐肺炎球菌疫苗在50岁及以上成人中的成本效果和预算影响,并分别分析美国黑人与非黑人队列。结果示PCV24预防的病例和死亡少于PCV21策略,但经济性不如PCV21;两者预算影响无明显差异。

要点

  • PCV24预防的肺炎球菌疾病病例和死亡少于PCV21策略。
  • PCV24经济性不如PCV21,其他疫苗同样不如PCV21。
  • PCV24与PCV21的预算影响无明显差异,但PCV21预防更多住院和死亡。

核心结论

  • 与仅依据成人肺炎球菌流行病学配制的PCV21相比,PCV24和其他依据儿童流行病学配制的疫苗在50岁及以上成人中经济性较差。
  • PCV21与PCV24使用的预算影响相似。

研究设计与样本

  • 马尔可夫决策分析模型比较PCV24与所有当前推荐肺炎球菌疫苗。
  • 按年龄接种可在50岁或50岁和65岁进行。
  • 分析分别检查美国黑人和非黑人假设队列,考虑和不考虑儿童肺炎球菌疫苗接种间接效应,使用种族特异性肺炎球菌疾病和疫苗接种数据。
  • 队列从社会和医疗保健视角在终身时间范围内追踪。
  • 模型参数来自美国数据,参数不确定性通过确定性和概率敏感性分析评估。

主要发现

  • 从社会和医疗保健视角,PCV24预防的肺炎球菌疾病病例和死亡少于使用PCV21的策略,但经济性不如PCV21。
  • 其他疫苗同样不如PCV21有利。
  • 加入儿童疫苗接种间接效应后,PCV24策略与PCV21策略相比仍不利。
  • 在概率敏感性分析中,在10万美元/质量调整生命年支付意愿阈值下,50岁和65岁接种PCV21在黑种人队列中99%的模型迭代中被首选,非黑人中为85%。
  • PCV24和PCV21的预算影响无实质性差异,但PCV21预防更多住院和死亡。

关键数值与推荐

  • 在10万美元/质量调整生命年支付意愿阈值下,50岁和65岁接种PCV21在黑种人队列中99%的模型迭代中被首选,非黑人中为85%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 24-valent pneumococcal conjugate vaccine (PCV24) is currently in development and could potentially be used in all adults aged 50 years and older. This study evaluated risk- and age-based PCV24 use to ascertain its potential public health effects, budget impact, and cost-effectiveness. A Markov decision analysis model compared PCV24 and all currently recommended pneumococcal vaccines. Age-based vaccination could occur at age 50 or at ages 50 and 65. The analysis separately examined hypothetical cohorts of U.S. Black and non-Black individuals with and without consideration of childhood pneumococcal vaccination indirect effects, using race-specific pneumococcal disease and vaccination data. Cohorts were tracked over a lifetime horizon from both societal and healthcare perspectives. Model parameters were derived from U.S. data and parameter uncertainty was evaluated through deterministic and probabilistic sensitivity analyses. Budgetary impact of 21-valent conjugate vaccine (PCV21), PCV24, and combinations of both at different ratios was also assessed. From societal and healthcare perspectives, PCV24 prevented fewer pneumococcal disease cases and deaths but was less economically favorable than strategies using PCV21. Other vaccines were similarly less favorable than PCV21. When adding childhood vaccination indirect effects, PCV24 strategies remained unfavorable compared to PCV21 strategies. In probabilistic sensitivity analyses, PCV21 at ages 50 and 65 was preferred in 99 % of model iterations for Black cohorts and 85 % for non-Blacks at a $100,000/QALY willingness-to-pay threshold. Budget impact for PCV24 and PCV21 were not substantially different but PCV21 prevented more hospitalizations and deaths. Compared to PCV21, which is formulated solely on adult pneumococcal epidemiology, PCV24 and other childhood epidemiology-formulated vaccines were less economically favorable among adults aged 50 and older. Budget impacts of PCV21 and PCV24 use were similar.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Altawalbeh SM, Wateska AR, Nowalk MP, et al. Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older. Vaccine. 2025. PMID: 40609266. doi:10.1016/j.vaccine.2025.127433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。